Sandbox:Sahar: Difference between revisions
No edit summary |
No edit summary |
||
Line 96: | Line 96: | ||
clinical features. | clinical features. | ||
| style="padding: 5px 5px; background: #FFFFE0;" align="center" | | | style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''I''' | ||
|'''B''' | |||
| style="padding: 5px 5px; background: #FFFFE0;" align="center" | | |||
|- | |- | ||
! colspan="4" style="padding: 5px 5px; background: #F5F5F5; " | Laboratory testing | ! colspan="4" style="padding: 5px 5px; background: #F5F5F5; " | Laboratory testing | ||
Line 109: | Line 111: | ||
clinical probability. | clinical probability. | ||
| style="padding: 5px 5px; background: #FFFFE0;" align="center" | | | style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: #FFFFE0;" align="center" | | | style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''B''' | ||
| | | | ||
|- | |- | ||
Line 122: | Line 124: | ||
diagnosis. | diagnosis. | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''C''' | ||
| | | | ||
|- | |- | ||
Line 135: | Line 137: | ||
tests should be considered. | tests should be considered. | ||
| style="padding: 5px 5px; background: #FFFFE0;" align="center" | | | style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''IIa''' | ||
| style="padding: 5px 5px; background: #FFFFE0;" align="center" | | | style="padding: 5px 5px; background: #FFFFE0;" align="center" |'''B''' | ||
| | | | ||
|- | |- | ||
Line 146: | Line 148: | ||
recommended. | recommended. | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''III''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |'''C''' | ||
| | | | ||
|- | |- | ||
Line 155: | Line 157: | ||
initial imaging investigation. | initial imaging investigation. | ||
! | !I | ||
! | !C | ||
! | ! | ||
|- | |- | ||
Line 173: | Line 175: | ||
|- | |- | ||
!TOE | !TOE | ||
! | !I | ||
! | !C | ||
! | ! | ||
|- | |- | ||
!CT | !CT | ||
! | !I | ||
! | !C | ||
! | ! | ||
|- | |- | ||
Line 198: | Line 200: | ||
|- | |- | ||
!CT | !CT | ||
! | !I | ||
! | !C | ||
! | ! | ||
|- | |- | ||
!MRI | !MRI | ||
!I | |||
!C | |||
! | ! | ||
|- | |||
!TOE | |||
!IIa | |||
!C | |||
! | ! | ||
|- | |||
!In case of initially negative | |||
imaging with persistence of | |||
suspicion of AAS, repetitive | |||
imaging (CT or MRI) is | |||
recommended. | |||
!I | |||
!C | |||
! | ! | ||
|- | |- | ||
! | !Chest X-ray may be | ||
! | |||
considered in cases of low | |||
clinical probability of AAS. | |||
!IIb | |||
!C | |||
! | ! | ||
|- | |||
!In case of uncomplicated | |||
Type B AD treated medically, | |||
repeated imaging (CT or | |||
MRI)e during the first days is | |||
recommended. | |||
!I | |||
!C | |||
! | ! | ||
|} | |} |
Revision as of 17:51, 24 December 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recomendacations | Class | Level | References |
---|---|---|---|
History and clinical assessment | |||
In all patients with suspected
AAS, pre-test probability assessment is recommended, according to the patient’s condition, symptoms, and clinical features. |
I | B | |
Laboratory testing | |||
In case of suspicion of AAS,
the interpretation of biomarkers should always be considered along with the pretest clinical probability. |
IIa | B | |
In case of low clinical
probability of AAS, negative D-dimer levels should be considered as ruling out the diagnosis. |
IIa | C | |
In case of intermediate clinical
probability of AAS with a positive (point-of-care) D-dimer test, further imaging tests should be considered. |
IIa | B | |
In patients with high probability
(risk score 2 or 3) of AD, testing of D-dimers is not recommended. |
III | C | |
Imaging | |||
TTE is recommended as an
initial imaging investigation. |
I | C | |
In unstabled patients with a
suspicion of AAS, the following imaging modalities are recommended according to local availability and expertise: |
|||
TOE | I | C | |
CT | I | C | |
In stable patients with a
suspicion of AAS, the following imaging modalities are recommended (or should be considered) according to local availability and expertise: |
|||
CT | I | C | |
MRI | I | C | |
TOE | IIa | C | |
In case of initially negative
imaging with persistence of suspicion of AAS, repetitive imaging (CT or MRI) is recommended. |
I | C | |
Chest X-ray may be
considered in cases of low clinical probability of AAS. |
IIb | C | |
In case of uncomplicated
Type B AD treated medically, repeated imaging (CT or MRI)e during the first days is recommended. |
I | C |